LimFlow SA
Paris
About LimFlow SA
LimFlow System is approved for sale in markets regulated by the CE Mark. Investigational device in the United States. Limited by U.S. federal law to investigational use only in the U.S. LimFlow is a game-changing technology that enables clinicians to bring new hope to end-stage chronic limb ischemia (CLI) patients, when all other revascularization efforts have been exhausted. By restoring perfusion to the ischemic foot through a completely novel, percutaneous procedure, the LimFlow System can relieve ischemic pain, promote wound healing, reduce amputations and restore mobility for patients when used as part of a multi-disciplinary team approach.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $72.7M
- Funding stage: M&A
- Last round: Series D (Apr 2022)
- Website: limflow.com
- Phone: +33.638.747.190
Industries & Categories
Emergency Medicine, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/limflow-sa-115211 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.